TP53 and lung adenocarcinoma: Furthermore, some common driver genes, including TP53 (p.K159X) and EGFR (p.E709 K and p.G719A) were no longer detected after therapy, indicating these mutations may contribute to sensitivity to chemotherapy, although the biological behavior of these mutations was not fully understood, our study demonstrates their potential effects on chemotherapy and improved our knowledge to lung adenocarcinoma mutation landscape.